Table2. Comparison of demographic factors, clinical features, and medications between lithium responders and non-responders

	<u>Alda≥7 (n=26)</u>	<u>Alda<7(n=70)</u>	P
	Mean (SD)	Mean (SD)	
Gender (M/F)	13/13	42/28	0.379
Age	52.54 (13.19)	53.26 (10.45)	0.993
Education duration (years)	13.58 (2.45)	13.44 (2.11)	0.876
JART-estimated premorbid IQ	99.85 (11.91)	101.76 (10.17)	0.501
Age at onset	35.23 (14.53)	33.79 (12.20)	0.837
Familial history (+/-)	13/13	32/38	0.708
HAM-D	0.81 (1.36)	2.97 (3.36)	<0.001
YMRS	1.15 (1.95)	1.20 (2.57)	0.977
PANSS-P	7.62 (1.17)	8.30 (2.21)	0.222
PANSS-N	8.04 (1.48)	11.37 (4.90)	< 0.001
Number of mood episodes	7.27 (4.13)	11.34 (7.33)	0.012
Psychotic features (+/-)	10/16	30/40	0.698
Lithium (+/-)	23/0	62/7	0.186
Valproic acid (+/-)	7/19	16/54	0.678
Carbamazepine (+/-)	3/23	8/62	0.619
FGA (+/-)	3/23	18/52	0.135
SGA (+/-)	5/21	37/33	0.003
Alda scale	7.58 (0.76)	3.36 (1.87)	<0.0001

Alda scale, The Retrospective Criteria of Long-Term Treatment Response in Research Subjects with Bipolar Disorder scale; BACS, Brief Assessment of Cognition in Schizophrenia; FGA, first-generation antipsychotic; HAM-D, Hamilton Rating Scale for Depression; JART, Japanese Adult Reading Test; PANSS-P, Positive symptoms assessed by Positive and Negative Syndrome Scale; PANSS-N, Negative symptoms assessed by Positive and Negative Syndrome Scale; SFS, Social Functional Scale; SGA, second-generation antipsychotic; YMRS, Young mania rating scale. *P values for the differences in the demographic/clinical variables and BACS performances (z-scores of subdomains and composite score) between the lithium responders and non-responders were determined by the chi-square, Mann–Whitney U or Student t tests as appropriate.